Grifols S.A. (GRFS) 16.08 $GRFS
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol
PR Newswire - Mon Jun 20, 7:00AM CDT
Hologic, Inc. (NASDAQ: HOLX) and Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) - market-leading partners committed to blood safety - announced today that the U.S. Food and Drug Administration (FDA) has approved use of the Procleix Zika virus blood screening assay on the Procleix Panther system under the agency's Investigational New Drug (IND) study protocol.
GRFS: 16.08 (+0.26), HOLX: 35.62 (+1.51)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.71 (+0.31), JAZZ: 145.00 (+2.06), GRFS: 16.08 (+0.26), PBYI: 33.65 (+2.12)
Singulex announces a $50 million investment by Grifols for a 20% stake in the company
PR Newswire - Tue May 31, 7:26AM CDT
Singulex, Inc., the leader in next generation immunodiagnostic technology powered by single molecule counting, announced today a partnership with Grifols, one of the world's largest plasma product manufacturers and a pioneer in the research and development of therapeutic alternatives designed to contribute to scientific development. Grifols has subscribed a share capital increase and holds a 20% stake in Singulex. The partnership provides Singulex US$50 million in exchange for Grifols' access to an exclusive worldwide license for the use and sale of Singulex' SMC technology for the screening of donor blood and plasma. Grifols' investment marks a major advancement in further ensuring the safety of blood and plasma products.
GRF: 7.82 (-0.16), GRFS: 16.08 (+0.26)
Grifols 2015 Annual Report on Form 20-F filed with the SEC on April 5, 2016
PR Newswire - Tue Apr 05, 6:12AM CDT
Grifols, S.A. ("Grifols"
(MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) announced that it has filed its 2015 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC" on April 5, 2016. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2015.
GRF: 7.82 (-0.16), GRFS: 16.08 (+0.26)
Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma
ACCESSWIRE - Fri Feb 05, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 05, 2016 / Park Lane Advisor has initiated coverage on the following equities: Biogen Inc. (NASDAQ: BIIB), Medivation Inc. (NASDAQ: MDVN), Grifols S.A. (NASDAQ: GRFS), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Free note on Biogen can be accessed at http://www.parklaneadvisor.com/ On Thursday, February 04, 2016, the NASDAQ Composite ended at 4,509.56, up 0.12%, the Dow Jones Industrial Average advanced 0.49%, to finish the day at 16,416.58, and the S&P 500 closed at 1,915.45, up 0.15%. The gains were broad based as five out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
MDVN: 59.26 (+0.37), BIIB: 238.62 (+4.02), AGIO: 48.50 (+1.43), GRFS: 16.08 (+0.26)
How it All Plays Out - Analyst Reports on KapStone Paper and Packaging, Heartland Express, Grifols and Knoll
ACCESSWIRE - Wed Jan 13, 7:35AM CST
NEW YORK, NY / ACCESSWIRE / January 13, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: KapStone Paper and Packaging Corp (NYSE: KS), Heartland Express Inc. (NASDAQ: HTLD), Grifols SA (NASDAQ: GRFS) and Knoll Inc. (NYSE: KNL). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
KNL: 24.61 (+0.29), HTLD: 17.36 (+0.27), KS: 15.51 (+0.78), GRFS: 16.08 (+0.26)
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 26.31 (+1.04), CVD: 106.42 (-0.71), JNJ: 117.38 (+0.92), ABBV: 61.31 (+0.92), ABT: 39.63 (+0.89), CBSTZ: 0.06 (unch), IMGN: 3.32 (+0.07), AMGN: 152.27 (+2.46), BMY: 72.64 (+0.33), GRFS: 16.08 (+0.26), GILD: 83.37 (+0.92), BAX: 45.96 (+1.02), AZN: 29.29 (+0.59), MRK: 57.68 (+0.64), NVS: 80.67 (+0.96), CELGZ: 1.45 (+0.01)
LifeSci Capital Initiates Coverage of Aradigm
ACCESSWIRE - Tue May 19, 9:08AM CDT
Developing Inhaled, Liposomal Antibiotics for Patients with Chronic Lung Diseases; Report Available here: www.lifescicapital.com/equity-research/aradigm/
GRFS: 16.08 (+0.26), ARDM: 4.34 (-0.11)
Plasma Fractionation Market worth $25,383.4 Million by 2019 - Key Player of Market Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy)
M2 - Wed Jan 21, 4:40AM CST
According to the new market research report The "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019", published by MarketsandMarkets, the Plasma Fractionation Market is expected to reach nearly $25,383.4 Million by 2019, growing at a CAGR of 8.9% from 2014 to 2019.
GRFS: 16.08 (+0.26)
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CRS: 34.29 (+1.10), ATI: 14.21 (+0.84), FUL: 46.78 (-0.19), CSTM: 4.86 (+0.33), GRFS: 16.08 (+0.26)
FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol
PR Newswire - Mon Jun 20, 7:00AM CDT
Hologic, Inc. (NASDAQ: HOLX) and Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) - market-leading partners committed to blood safety - announced today that the U.S. Food and Drug Administration (FDA) has approved use of the Procleix Zika virus blood screening assay on the Procleix Panther system under the agency's Investigational New Drug (IND) study protocol.
GRFS: 16.08 (+0.26), HOLX: 35.62 (+1.51)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.71 (+0.31), JAZZ: 145.00 (+2.06), GRFS: 16.08 (+0.26), PBYI: 33.65 (+2.12)
Singulex announces a $50 million investment by Grifols for a 20% stake in the company
PR Newswire - Tue May 31, 7:26AM CDT
Singulex, Inc., the leader in next generation immunodiagnostic technology powered by single molecule counting, announced today a partnership with Grifols, one of the world's largest plasma product manufacturers and a pioneer in the research and development of therapeutic alternatives designed to contribute to scientific development. Grifols has subscribed a share capital increase and holds a 20% stake in Singulex. The partnership provides Singulex US$50 million in exchange for Grifols' access to an exclusive worldwide license for the use and sale of Singulex' SMC technology for the screening of donor blood and plasma. Grifols' investment marks a major advancement in further ensuring the safety of blood and plasma products.
GRF: 7.82 (-0.16), GRFS: 16.08 (+0.26)
Grifols 2015 Annual Report on Form 20-F filed with the SEC on April 5, 2016
PR Newswire - Tue Apr 05, 6:12AM CDT
Grifols, S.A. ("Grifols"
(MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) announced that it has filed its 2015 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC" on April 5, 2016. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2015. GRF: 7.82 (-0.16), GRFS: 16.08 (+0.26)
Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma
ACCESSWIRE - Fri Feb 05, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 05, 2016 / Park Lane Advisor has initiated coverage on the following equities: Biogen Inc. (NASDAQ: BIIB), Medivation Inc. (NASDAQ: MDVN), Grifols S.A. (NASDAQ: GRFS), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Free note on Biogen can be accessed at http://www.parklaneadvisor.com/ On Thursday, February 04, 2016, the NASDAQ Composite ended at 4,509.56, up 0.12%, the Dow Jones Industrial Average advanced 0.49%, to finish the day at 16,416.58, and the S&P 500 closed at 1,915.45, up 0.15%. The gains were broad based as five out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
MDVN: 59.26 (+0.37), BIIB: 238.62 (+4.02), AGIO: 48.50 (+1.43), GRFS: 16.08 (+0.26)
How it All Plays Out - Analyst Reports on KapStone Paper and Packaging, Heartland Express, Grifols and Knoll
ACCESSWIRE - Wed Jan 13, 7:35AM CST
NEW YORK, NY / ACCESSWIRE / January 13, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: KapStone Paper and Packaging Corp (NYSE: KS), Heartland Express Inc. (NASDAQ: HTLD), Grifols SA (NASDAQ: GRFS) and Knoll Inc. (NYSE: KNL). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
KNL: 24.61 (+0.29), HTLD: 17.36 (+0.27), KS: 15.51 (+0.78), GRFS: 16.08 (+0.26)
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 26.31 (+1.04), CVD: 106.42 (-0.71), JNJ: 117.38 (+0.92), ABBV: 61.31 (+0.92), ABT: 39.63 (+0.89), CBSTZ: 0.06 (unch), IMGN: 3.32 (+0.07), AMGN: 152.27 (+2.46), BMY: 72.64 (+0.33), GRFS: 16.08 (+0.26), GILD: 83.37 (+0.92), BAX: 45.96 (+1.02), AZN: 29.29 (+0.59), MRK: 57.68 (+0.64), NVS: 80.67 (+0.96), CELGZ: 1.45 (+0.01)
LifeSci Capital Initiates Coverage of Aradigm
ACCESSWIRE - Tue May 19, 9:08AM CDT
Developing Inhaled, Liposomal Antibiotics for Patients with Chronic Lung Diseases; Report Available here: www.lifescicapital.com/equity-research/aradigm/
GRFS: 16.08 (+0.26), ARDM: 4.34 (-0.11)
Plasma Fractionation Market worth $25,383.4 Million by 2019 - Key Player of Market Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy)
M2 - Wed Jan 21, 4:40AM CST
According to the new market research report The "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019", published by MarketsandMarkets, the Plasma Fractionation Market is expected to reach nearly $25,383.4 Million by 2019, growing at a CAGR of 8.9% from 2014 to 2019.
GRFS: 16.08 (+0.26)
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CRS: 34.29 (+1.10), ATI: 14.21 (+0.84), FUL: 46.78 (-0.19), CSTM: 4.86 (+0.33), GRFS: 16.08 (+0.26)
